{"title":"癌症试验主要终点的变化。","authors":"","doi":"10.1136/dtb.2023.000064","DOIUrl":null,"url":null,"abstract":"<p><p><b>Overview of:</b> Florez MA, Jaoude JA, Patel RR, et al. Incidence of primary end point changes among active cancer phase 3 randomized clinical trials.<i>JAMA Netw Open</i>2023;6:e2313819.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"5"},"PeriodicalIF":0.0000,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Changes in primary endpoints in cancer trials.\",\"authors\":\"\",\"doi\":\"10.1136/dtb.2023.000064\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Overview of:</b> Florez MA, Jaoude JA, Patel RR, et al. Incidence of primary end point changes among active cancer phase 3 randomized clinical trials.<i>JAMA Netw Open</i>2023;6:e2313819.</p>\",\"PeriodicalId\":11277,\"journal\":{\"name\":\"Drug and Therapeutics Bulletin\",\"volume\":\" \",\"pages\":\"5\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug and Therapeutics Bulletin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/dtb.2023.000064\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and Therapeutics Bulletin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/dtb.2023.000064","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
概述：Florez MA, Jaoude JA, Patel RR, et al. Inidence of primary end point changes among active cancer phase 3 randomized clinical trials.JAMA Netw Open2023;6:e2313819.
Overview of: Florez MA, Jaoude JA, Patel RR, et al. Incidence of primary end point changes among active cancer phase 3 randomized clinical trials.JAMA Netw Open2023;6:e2313819.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
